医学
利奈唑啉
内科学
置信区间
万古霉素
人口
不利影响
随机对照试验
外科
临床终点
抗菌剂
抗生素
金黄色葡萄球菌
细菌
环境卫生
微生物学
生物
遗传学
作者
Mark H. Wilcox,Kenneth J. Tack,Emilio Bouza,Daniel Herr,B. Ruf,M. Marian Ijzerman,Rodney Croos‐Dabrera,M Künkel,Charles Knirsch
摘要
Linezolid demonstrated microbiologic success rates noninferior to those for vancomycin in patients with cSSSIs and CRBSIs caused by gram-positive organisms. Patients with catheter-related infections must be carefully investigated for the heterogeneous underlying causes of high morbidity and mortality, particularly for infections with gram-negative organisms.
科研通智能强力驱动
Strongly Powered by AbleSci AI